Lexicon Pharmaceuticals
LXRX
91 hedge funds and large institutions have $150M invested in Lexicon Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 24 closing their positions.
77% more call options, than puts
Call options by funds: $288K | Put options by funds: $163K
16% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 25
2.88% less ownership
Funds ownership: 100.21% → 97.33% (-2.9%)
16% less funds holding
Funds holding: 108 → 91 (-17)
30% less capital invested
Capital invested by funds: $214M → $150M (-$63.8M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
71% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lazard Asset Management
New York
|
+$1.78M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.07M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$875K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$650K |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$594K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.09M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.17M |
| 3 |
Morgan Stanley
New York
|
-$1.12M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1M |
| 5 |
Two Sigma Advisers
New York
|
-$909K |
LXRX Hedge Fund Activity: Q3 2020 in Review
91 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2020, worth a combined $150M — down 30% from $214M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of LXRX and 7 opened new positions — a net loss of 17 holders — while 25 trimmed existing stakes and 29 added.
The largest buyer was Lazard Asset Management, adding an estimated $1.78M. The largest seller was Fidelity Investments, cutting an estimated $3.09M.
- 91 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2020, down from 108 in Q2 2020.
- Funds reported $150M of Lexicon Pharmaceuticals stock for Q3 2020, down 30% quarter-over-quarter.
- 7 funds opened new Lexicon Pharmaceuticals positions in Q3 2020 and 24 closed out, a net change of -17 holders.
- The largest Lexicon Pharmaceuticals buyer in Q3 2020 was Lazard Asset Management, an estimated $1.78M added.
- The largest Lexicon Pharmaceuticals seller in Q3 2020 was Fidelity Investments, an estimated $3.09M sold.
Based on aggregated 13F filings for Q3 2020.